South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain
/PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of...
Stay updated with breaking news from Neil Singla. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of...
BERWYN, Pa.--(BUSINESS WIRE)--#earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its...
Virpax® Pharmaceuticals, Inc. , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral... | May 12, 2023
“The EDC is no longer the bottleneck in study startup. We are reducing overall study start times from three months to four-to-five weeks...